Combination of TATE and PD-1 Inhibitor in Liver Cancer (TATE-PD1)

NCT03259867 PHASE2 RECRUITING

This is a multi-center, open-label phase IIA study that investigates the preliminary efficacy of Trans-arterial Tirapazamine Embolization (TATE) treatment of liver cancer followed by a PD-1 checkpoint inhibitor (nivolumab). Patients with two types of cancers will be enrolled, advanced hepatocellular carcinoma (HCC),and metastatic gastric cancer. All enrolled patients need to have liver lesions and have progressed on a prior immune checkpoint inhibitor.

Details

Lead sponsor	Teclison Ltd.
Phase	PHASE2
Status	RECRUITING
Enrolment	54
Start date	Sat Jul 01 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Wed Jun 30 2027 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Hepatocellular Carcinoma
• Gastric Cancer

Interventions

• Nivolumab Injectable Product
• Trans-arterial tirapazamine embolization

Countries

United States